<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRP</journal-id><journal-title-group><journal-title>Asian Case Reports in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2328-045X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRP.2019.72002</article-id><article-id pub-id-type="publisher-id">ACRP-30510</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRP20190200000_66364518.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血浆NBNP测定在KD诊断中的价值研究
  Study on the Value of Plasma N-Terminal Brain Natriuretic Peptide in the Diagnosis of Children with Kawasaki Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吕</surname><given-names>菊红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>江</surname><given-names>逊</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>红茹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邓</surname><given-names>峰</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>宝鸡市中心医院儿科，陕西 宝鸡</addr-line></aff><aff id="aff3"><addr-line>空军军医大学唐都医院儿科，陕西 西安</addr-line></aff><aff id="aff5"><addr-line>宝鸡市疾病预防控制中心，陕西 宝鸡</addr-line></aff><aff id="aff4"><addr-line>西安交通大学附属宝鸡市中心医院儿科，陕西 宝鸡</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>05</month><year>2019</year></pub-date><volume>07</volume><issue>02</issue><fpage>7</fpage><lpage>14</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：分析血浆NBNP水平测定对KD患儿临床诊断价值，旨在为相关临床与研究工作提供参考。方法：采用病例对照方法，以KD组为病例组，以同期呼吸道感染住院患儿为对照组，检测结果采用统计学有关方法进行分析。结果：病例组(KD)急性期NBNP水平(1573.51 pg/L &#177; 237.06 pg/L)明显高于对照组(226.07 pg/mL &#177; 87.68 pg/mL)，二者之间具有显著性差异，P &lt; 0.001；病例组恢复期NBNP水平有所下降(455.51 pg/mL &#177; 26.83 pg/mL)，但仍高于对照组，二者之间仍具有显著性差异，P &lt; 0.001；病例组各种类型KD的NBNP水平均高于对照组，具有显著性差异，P &lt; 0.001；血浆NBNP &gt; 300 pg/mL对诊断KD的敏感性为95.56%，特异性为94.17%。结论：血浆NBNP水平测定在KD临床诊断具有一定特异性和敏感性，可作为临床诊断儿童KD的重要参考指标。
   Objective: To analyze the value of plasma N-terminal brain natriuretic peptide level in the clinical diagnosis of children with Kawasaki disease, and to provide reference for relevant clinical and re-search work. Methods: The case-control method was used. The Kawasaki disease group was used as the case group. The hospitalized children with respiratory infection at the same time were used as the control group. The test results were analyzed by statistical methods. Results: The NBNP level (1573.51 pg/L &#177; 237.06 pg/L) in the acute phase of the case group was significantly higher than that in the control group (226.07 pg/mL &#177; 87.68 pg/mL), and there was a significant difference between the two, P &lt; 0.001. The NBNP level in the recovery group of the case group decreased (455.51 pg/mL &#177; 26.83 pg/mL), but it was still higher than the control group, and there was still a significant difference between the two, P &lt; 0.001. The NBNP levels of various types in the case group were higher than those in the control group, with significant difference, P &lt; 0.001. The sensitivity of plasma NBNP &gt; 300 pg/mL to diagnosis of KD was 95.56% and the specificity was 94.17%. Conclusion: The determination of plasma NBNP level has certain specificity and sensitivity in the clinical diagnosis of KD, and it can be used as an important reference index for clinical diagnosis of KD in children.
 
</p></abstract><kwd-group><kwd>血浆NBNP，川崎病，临床诊断, Plasma N-Terminal Brain Natriuretic Peptide</kwd><kwd> Kawasaki Disease Child</kwd><kwd> Clinical Diagnosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>血浆NBNP测定在KD诊断中的价值研究<sup> </sup></title><p>吕菊红<sup>1,2</sup>，江逊<sup>3</sup>，马红茹<sup>1,2</sup>，邓峰<sup>4,5*</sup></p><p><sup>1</sup>宝鸡市中心医院儿科，陕西 宝鸡</p><p><sup>2</sup>西安交通大学附属宝鸡市中心医院儿科，陕西 宝鸡</p><p><sup>3</sup>空军军医大学唐都医院儿科，陕西 西安</p><p><sup>4</sup>宝鸡市疾病预防控制中心，陕西 宝鸡</p><p><sup>5</sup>西安交通大学宝鸡预防医学研究院，陕西 宝鸡</p><disp-formula id="hanspub.30510-formula3"><graphic xlink:href="//html.hanspub.org/file/1-2460089x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年5月6日；录用日期：2019年5月22日；发布日期：2019年5月29日</p><disp-formula id="hanspub.30510-formula4"><graphic xlink:href="//html.hanspub.org/file/1-2460089x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：分析血浆NBNP水平测定对KD患儿临床诊断价值，旨在为相关临床与研究工作提供参考。方法：采用病例对照方法，以KD组为病例组，以同期呼吸道感染住院患儿为对照组，检测结果采用统计学有关方法进行分析。结果：病例组(KD)急性期NBNP水平(1573.51 pg/L &#177; 237.06 pg/L)明显高于对照组(226.07 pg/mL &#177; 87.68 pg/mL)，二者之间具有显著性差异，P &lt; 0.001；病例组恢复期NBNP水平有所下降(455.51 pg/mL &#177; 26.83 pg/mL)，但仍高于对照组，二者之间仍具有显著性差异，P &lt; 0.001；病例组各种类型KD的NBNP水平均高于对照组，具有显著性差异，P &lt; 0.001；血浆NBNP &gt; 300 pg/mL对诊断KD的敏感性为95.56%，特异性为94.17%。结论：血浆NBNP水平测定在KD临床诊断具有一定特异性和敏感性，可作为临床诊断儿童KD的重要参考指标。</p><p>关键词 :血浆NBNP，川崎病，临床诊断</p><disp-formula id="hanspub.30510-formula5"><graphic xlink:href="//html.hanspub.org/file/1-2460089x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2460089x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2460089x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>川崎病(Kawasaki disease, KD)是小儿常见的发热性疾病，其主要病理改变为全身非特异性血管炎性反应。目前，KD的诊断仍以临床症状为主要依据 [<xref ref-type="bibr" rid="hanspub.30510-ref1">1</xref>] ，尚缺乏特异性实验室检测指标 [<xref ref-type="bibr" rid="hanspub.30510-ref2">2</xref>] ，许多患者累及冠状动脉，甚至成为小儿常见的后天性心脏病主要因素 [<xref ref-type="bibr" rid="hanspub.30510-ref3">3</xref>]。近年来，KD患儿特别是不完全KD患儿逐年增多，因其临床表现不典型，更易造成误诊、延迟治疗，甚至造成严重后果 [<xref ref-type="bibr" rid="hanspub.30510-ref4">4</xref>]。因此，探寻KD特异性实验室检测诊断指标显得十分重要。有研究发现，与其他病毒感染性疾病相比，KD患儿血浆N末端脑钠肽(NT-pro brain natriuretic peptide, NBNP)水平有明显改变，有一定的特异性，可望作为KD的生化学标记物 [<xref ref-type="bibr" rid="hanspub.30510-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref6">6</xref>]。本文通过病例对照研究方法，探讨了血浆NBNP水平测定在KD临床诊断中价值。</p></sec><sec id="s4"><title>2. 研究对象与方法</title><sec id="s4_1"><title>2.1. 研究对象</title><p>本研究以2011年1月至2017年12月在宝鸡市中心医院儿科住院的255例患儿为研究对象，其中：135例KD患儿为病例组，120例以呼吸道感染住院的患儿为对照组。</p><sec id="s4_1_1"><title>2.1.1. 病例组</title><p>1) 纳入标准：① 2011年1月至2017年12月在宝鸡市中心医院儿科住院6岁及以下患儿；② 符合我国完全KD诊断标准者，即具备6项主要临床表现中至少5项或具备4项，且心脏超声发现冠脉扩张或冠脉瘤者；③ 符合我国不完全KD诊断标准者，即发热5天或以上，有至少2项KD主要临床表现，具备炎症反应指标明显升高；④ 既往无心血管疾病者；⑤ 近期未参加同类相关研究者。2) 排除标准：① 2011年1月至2017年12月以外时间在我院儿科住院患儿；② 年龄&gt;6岁者；③ 既不符合典型KD诊断标准，又不符合不完全KD诊断标准者；④ 既往有心血管疾病者；⑤ 近期参加同类相关研究者。3) 按照上述纳入和排除标准，最终纳入KD病例组的患儿135例，其中：0~2岁53例、2~4岁46例、4~6岁36例；男性80例，女性55例；完全型78例，不完全型57例。</p></sec><sec id="s4_1_2"><title>2.1.2. 对照组</title><p>1) 纳入标准：① 2011年1月至2017年12月在我院儿科住院6岁及以下患儿；② 符合呼吸道感染诊断标准者；③ 心电图、心肌酶检测排除心肌受累者；④ 既往无心肺肾疾病者；⑤ 既往无KD病史者；⑥ 近期未参加同类相关研究者。2) 排除标准：① 2011年1月至2017年12月以外时间在我院儿科住院患儿；② 年龄&gt;6岁者；③ 不符合呼吸道感染诊断标准者；④查心电图、心肌酶有心肌受累者；④ 既往有心肺肾疾病者；⑤ 既往有KD病史者；⑥ 近期参加同类相关研究者。3) 按照上述纳入和排除标准，最终纳入对照患儿120例，其中：0~2岁39例、2~4岁41例、4~6岁40例；男性58例，女性62例；上呼吸道感染65例，肺炎55例。</p></sec><sec id="s4_1_3"><title>2.1.3. 病例组与对照组可比性分析</title><p>经χ<sup>2</sup>检验，病例组与对照组在年龄段分布、男女性别之间均无统计学显著性差异，P &gt; 0.05，说明两组具有较好可比性。</p></sec></sec><sec id="s4_2"><title>2.2. 研究方法</title><p>1) 本研究通过比较分析病例组和对照组患儿NBNP水平变化情况，探讨NBNP测定在KD临床诊断中的价值。</p><p>2) 两组患儿于入院当日采集静脉血进行血浆NBNP检测。仪器采用Cobas e E411电化学免疫发光分析仪，试剂盒为德国罗氏原装配套，NBNP测定采用电化学免疫发光法进行；同时，进行CRP、ESR、WBC测定。KD组同时进行心脏超声心动图检查，以评价冠状动脉有无损害。冠状动脉病变诊断标准采用第7次世界小儿KD研讨会修订的诊断标准 [<xref ref-type="bibr" rid="hanspub.30510-ref7">7</xref>]。KD组在疾病恢复期重新测定NBNP，并行超声心动图检查。</p><p>3) NBNP水平数据采用(x &#177; s)进行描述，两组间和同组治疗前后比较采用t检验，数据采用SPSS 10.0软件进行处理，P &lt; 0.05为有统计学显著性差异。</p></sec></sec><sec id="s5"><title>3. 研究结果</title><sec id="s5_1"><title>3.1 病例组急性期与对照组血浆NBNP、CRP、ESR、WBC水平比较</title><p>病例组急性期血浆NBNP水平显著高于对照组，两者具有显著性差异(P &lt; 0.001)，病例组急性期CRP、ESR、WBC水平与对照组比较，无统计学意义(P &gt; 0.05)，具体见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of plasma NBNP and other indicators in the acute and control groups of the case grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >病例组(135)</th><th align="center" valign="middle" >对照组(120)</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >CRP (mg/L)</td><td align="center" valign="middle" >52.76 &#177; 24.57</td><td align="center" valign="middle" >38.65 &#177; 21.23</td><td align="center" valign="middle" >0.019</td><td align="center" valign="middle" >0.985</td></tr><tr><td align="center" valign="middle" >ESR (mm/h)</td><td align="center" valign="middle" >45.38 &#177; 17.55</td><td align="center" valign="middle" >39.77 &#177; 24.42</td><td align="center" valign="middle" >1.938</td><td align="center" valign="middle" >0.056</td></tr><tr><td align="center" valign="middle" >WBC (&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >16.69 &#177; 3.42</td><td align="center" valign="middle" >13.30 &#177; 3.61</td><td align="center" valign="middle" >0.471</td><td align="center" valign="middle" >0.639</td></tr><tr><td align="center" valign="middle" >NBNP(pg/mL)</td><td align="center" valign="middle" >1573.51 &#177; 237.06</td><td align="center" valign="middle" >226.07 &#177; 87.68</td><td align="center" valign="middle" >33.264</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表1. 病例组急性期和对照组血浆NBNP等指标比较</p></sec><sec id="s5_2"><title>3.2. 病例组急性期、恢复期与对照组NBNP水平比较</title><p>表2显示，病例组急性期NBNP水平(1573.51 pg/mL &#177; 237.06 pg/mL)明显高于对照组(226.07 pg/mL &#177; 87.68 pg/mL)，P &lt; 0.001。尽管病例组恢复期NBNP水平(455.51 pg/mL &#177; 26.83 pg/mL)较急性期(1573.51 pg/mL &#177; 237.06 pg/mL)明显降低，P &lt; 0.001，但是病例组恢复期NBNP水平(455.51 pg/mL &#177; 26.83 pg/mL)仍高于对照组(226.07 pg/mL &#177; 87.68 pg/mL)，P &lt; 0.001。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of NBNP levels in acute, recovery and control groups of case grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >例数(例)</th><th align="center" valign="middle" >NBNP水平(pg/mL)</th><th align="center" valign="middle" >比较组</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >对照组(1)</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >226.07 &#177; 87.68</td><td align="center" valign="middle" >1, 2</td><td align="center" valign="middle" >33.264</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >病例组急性期(2)</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >1573.51 &#177; 237.06</td><td align="center" valign="middle" >2, 3</td><td align="center" valign="middle" >34.341</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >病例组恢复期(3)</td><td align="center" valign="middle" >135</td><td align="center" valign="middle" >455.51 &#177; 26.83</td><td align="center" valign="middle" >1, 3</td><td align="center" valign="middle" >4.568</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表2. 病例组急性期、恢复期与对照组NBNP水平比较</p></sec><sec id="s5_3"><title>3.3. 病例组完全型与不完全型急性期NBNP水平比较</title><p>病例组完全型与不完全型急性期血浆NBNP水平比较，两者无显著性差异(P &gt; 0.05)，具体见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of plasma NBNP levels between complete and incomplete types in the KD grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >例数(例)</th><th align="center" valign="middle" >NBNP水平(pg/mL)</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >完全型</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >1249.48 &#177; 226.73</td><td align="center" valign="middle"  rowspan="2"  >0.830</td><td align="center" valign="middle"  rowspan="2"  >0.411</td></tr><tr><td align="center" valign="middle" >不完全型</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >1409.56.96 &#177; 254.04</td></tr></tbody></table></table-wrap><p>表3. KD组完全型与不完全型血浆NBNP水平比较</p></sec><sec id="s5_4"><title>3.4. 病例组急性期有冠脉损伤组与无冠脉损伤组NBNP水平比较</title><p>病例组患儿急性期均进行超声心动图检查，其中出现冠状动脉扩张(Coronary artery dilatation, CAD) 82例，根据有无合并CAD分为冠状动脉病变组与冠状动脉正常组，其中冠状动脉病变组NBNP水平为1333.35 pg/mL &#177; 277.28 pg/mL，冠状动脉正常组NBNP水平为1235.96 pg/mL &#177; 205.30 pg/mL，两组的NBNP水平差异无统计学意义(P &gt; 0.05)，具体见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of plasma NBNP levels in acute KD group and non-coronary injury group in KD grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >例数(例)</th><th align="center" valign="middle" >NBNP水平(pg/mL)</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >冠脉损伤组</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >1333.35 &#177; 277.28</td><td align="center" valign="middle"  rowspan="2"  >1.377</td><td align="center" valign="middle"  rowspan="2"  >0.180</td></tr><tr><td align="center" valign="middle" >无冠脉损伤组</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >1235.96 &#177; 205.30</td></tr></tbody></table></table-wrap><p>表4. KD组急性期冠脉损伤组与无冠脉损伤组血浆NBNP水平比较</p></sec><sec id="s5_5"><title>3.5. 病例组各类型KD的NBNP水平与对照组比较</title><p>如表5所示，各种类型KD的血浆NBNP水平与对照组之间均存在显著性差异(P &lt; 0.001)。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Plasma NBNP levels for each type of KD compared with control</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数(例)</th><th align="center" valign="middle" >NBNP水平(pg/mL)</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >120</td><td align="center" valign="middle" >226.07</td><td align="center" valign="middle" >87.68</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >KD冠脉损伤组</td><td align="center" valign="middle" >82</td><td align="center" valign="middle" >1333.35</td><td align="center" valign="middle" >277.28</td><td align="center" valign="middle" >42.26</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >KD无冠脉损伤组</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >1235.96</td><td align="center" valign="middle" >205.30</td><td align="center" valign="middle" >50.30</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >KD完全型</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >1249.48</td><td align="center" valign="middle" >226.73</td><td align="center" valign="middle" >46.32</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >KD不完全型</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >1409.56</td><td align="center" valign="middle" >254.04</td><td align="center" valign="middle" >48.26</td><td align="center" valign="middle" >&lt;0.001</td></tr></tbody></table></table-wrap><p>表5. 各类型KD的血浆NBNP水平与对照组比较情况</p></sec><sec id="s5_6"><title>3.6. NBNP参考诊断临界值</title><p>病例组急性期血浆NBNP &gt; 300 pg/mL者有129例，NBNP &lt; 300 pg/mL者有6例，对照组NBNP &gt; 300 pg/mL者有7例，NBNP &lt; 300 pg/mL者有113例，血浆NBNP诊断KD的敏感性、特异性见表6。从表6可以看出，血浆NBNP诊断KD的敏感性为95.56%，特异性为94.17%。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Comparison of plasma NBNP levels in the acute phase of KD compared with the control grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >NBNP(pg/mL)</th><th align="center" valign="middle" >KD急性期</th><th align="center" valign="middle" >对照组</th></tr></thead><tr><td align="center" valign="middle" >&gt;300</td><td align="center" valign="middle" >129</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >&lt;300</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >113</td></tr></tbody></table></table-wrap><p>表6. KD急性期血浆NBNP水平与对照组比较情况</p></sec></sec><sec id="s6"><title>4. 讨论</title><sec id="s6_1"><title>4.1. 国内外有关情况</title><p>自从全球首个KD研究报道至今，已过去了半个多世纪 [<xref ref-type="bibr" rid="hanspub.30510-ref8">8</xref>] ，期间尽管日本、美国、中国等对KD诊断标准进行了多轮修订，但目前仍以主要临床症状为诊断依据 [<xref ref-type="bibr" rid="hanspub.30510-ref9">9</xref>] - [<xref ref-type="bibr" rid="hanspub.30510-ref16">16</xref>]。而临床症状的判断是否及时、准确多依赖于临床医师实践经验。一项来自英国的调查结果显示，KD早期诊断或不完全KD诊断在英国全科医生甚至二级保健医生中存在困难 [<xref ref-type="bibr" rid="hanspub.30510-ref17">17</xref>]。有研究结果显示，KD儿童心脏病并发症高主要源于诊疗不及时 [<xref ref-type="bibr" rid="hanspub.30510-ref18">18</xref>]。近年来，国内外有关KD诊断的实验室检测指标方面研究逐渐增多。有研究指出，即使在没有经典临床症状的情况下，任何长期发热和兼容的实验室特征的婴儿也应该考虑KD诊断 [<xref ref-type="bibr" rid="hanspub.30510-ref19">19</xref>]。有研究表明，通过在急性KD炎症高峰期之前重复检查有关实验室指标的变化，有助于早期诊断KD [<xref ref-type="bibr" rid="hanspub.30510-ref20">20</xref>]。2017年美国最新发布KD诊断标准也指出，在主要临床特征基础上，可参考部分实验室检测指标 [<xref ref-type="bibr" rid="hanspub.30510-ref15">15</xref>]。有研究指出，NBNP是反映KD急性期心肌活动的较好指标，尤其是不完全KD患者，可能是KD诊断的一个有效附加指标 [<xref ref-type="bibr" rid="hanspub.30510-ref21">21</xref>]。有研究表示，血浆NBNP水平升高可作为早期KD诊断的实验室指标 [<xref ref-type="bibr" rid="hanspub.30510-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref24">24</xref>]。尽管国内外学者在KD诊断的实验室检测指标方面进行了一些探索，但尚未在更大范围形成共识 [<xref ref-type="bibr" rid="hanspub.30510-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref25">25</xref>]。</p></sec><sec id="s6_2"><title>4.2. 本研究相关情况</title><p>1) 本研究通过病例对照研究设计，纳入255例患儿作为研究对象，与既往同类研究 [<xref ref-type="bibr" rid="hanspub.30510-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref28">28</xref>] 相比，样本较多，提高了研究结果的信度。2) 本研究的病例组和对照组均有严格的纳入与排除标准，两组样本确定后，又对两组的可比性进行了分析，确保研究结果科学可靠。3) 本研究结果显示，病例组急性期血浆NBNP水平明显高于对照组，两者之间具有显著性差异(P &lt; 0.001)，而病例组急性期CRP、ESR、WBC水平与对照组相比，无显著性差异(P &gt; 0.05) (见表1)，提示血浆NBNP水平明显升高可作为诊断急性期KD的重要参考指标。同时，尽管病例组恢复期血浆NBNP水平较病例组急性期明显下降，但仍高于对照组，且与对照组之间仍具显著性差异(P &lt; 0.001) (见表2)，说明血浆NBNP水平较高可作为KD患儿与其它感染性疾病鉴别诊断的参考依据。此外，病例组急性期有冠脉损伤、无冠脉损伤、完全型、不完全型KD患儿的血浆NBNP水平均较高(&gt;1200 pg/mL)，相比而言，不完全型和有冠脉损伤KD患儿组的血浆NBNP水平更高(&gt;1300 pg/mL)，但四种类型KD患儿急性期血浆NBNP水平之间均无显著性差异(P &gt; 0.05)，但与对照组相比，均有显著性差异(P &lt; 0.001) (见表3~5)，说明血浆NBNP水平较高在各种类型KD患儿急性期均具有较好诊断或鉴别诊断参考价值。4) 尽管上述结果定性地显示了血浆NBNP水平较高在各种类型KD患儿诊断或鉴别诊断中具有一定价值，但尚未定量回答上述问题。为此，本研究对病例组急性期NBNP水平做了定量分析。首先，考虑到对照组患儿最高NBNP值为315 pg/mL，初步将NBNP值315 pg/mL作为KD参考诊断的最低值；其次，考虑到病例组恢复期最低NBNP为430pg/mL，再次将NBNP值430 pg/mL作为KD参考诊断的最高值；第三，在NBNP值315 pg/mL~430 pg/mL之间，对病例组急性期和对照组的病例分布情况进行逐步比较分析，最终发现，当NBNP &gt; 300 pg/mL时，该临界值在诊断KD的敏感性为95.56%，特异性为94.17%。综上，本研究结果不但定性地显示了血浆NBNP水平较高在各种类型KD患儿诊断或鉴别诊断中具有一定价值，而且定量地提出了KD诊断的临界参考值。</p></sec><sec id="s6_3"><title>4.3. 血浆NBNP测定在KD诊断中价值</title><p>1) 理论上，当心室负荷增加或室壁张力增高及血管发生炎症时均可刺激心室分泌BNP，并分解产生NBNP进入血液循环，且NBNP浓度会超过BNP 2~10倍，半衰期长、稳定好，可以作为患儿心功能损害判定的重要指标 [<xref ref-type="bibr" rid="hanspub.30510-ref29">29</xref>]。实践中，学界普遍认为NBNP水平是反映患儿心功能损害和心衰严重程度较为敏感指标 [<xref ref-type="bibr" rid="hanspub.30510-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.30510-ref32">32</xref>] ，即血浆NBNP水平与心血管受损程度具有密切关系。2) 如前所述，KD主要病理改变为全身非特异性血管炎性反应。理论上，当患儿发生KD时，其血浆NBNP水平会升高。但是，引起患儿血浆NBNP水平升高的疾病种类较多，单靠NBNP水平升高难以确定患儿是否为KD，即血浆NBNP水平升高并非KD诊断的独特指标。3) 尽管情况如此，但为了提高KD早期诊治水平，减少冠脉损伤甚至后天性心脏病的发生，根据本研究结果，仍建议在结合KD主要临床症状基础上，尽早开展患儿血浆NBNP水平测定，以尽早诊断与治疗KD患儿。综上，血浆NBNP测定在KD诊断中具有一定的参考价值。</p></sec></sec><sec id="s7"><title>文章引用</title><p>吕菊红,江 逊,马红茹,邓 峰. 血浆NBNP测定在KD诊断中的价值研究Study on the Value of Plasma N-Terminal Brain Natriuretic Peptide in the Diagnosis of Children with Kawasaki Disease[J]. 亚洲儿科病例研究, 2019, 07(02): 7-14. https://doi.org/10.12677/ACRP.2019.72002</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30510-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">余艳萍, 阿布来提•阿不都哈尔. 川崎病诊断与治疗新进展[J]. 中华临床医师杂志(电子版), 2016, 10(4): 566-570.</mixed-citation></ref><ref id="hanspub.30510-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">杨晓东, 黄敏. 川崎病诊断实验室指标及其临床价值[J]. 中国实用儿科杂志, 2013, 28(7): 491-494.</mixed-citation></ref><ref id="hanspub.30510-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Agarwal, S. and Agrawal, D.K. (2017) Kawasaki Disease: Etiopatho-Genesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247-258. https://doi.org/10.1080/1744666X.2017.1232165</mixed-citation></ref><ref id="hanspub.30510-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">谢添. 川崎病的治疗与随访[J]. 国际儿科学杂志, 2017, 44(11): 757-760+764.</mixed-citation></ref><ref id="hanspub.30510-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">杨芳, 陈琅, 沈晓丽, 等. N端脑钠肽前体在小儿川崎病诊断中的价值[J]. 临床儿科杂志, 2010, 28(7): 630-632.</mixed-citation></ref><ref id="hanspub.30510-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">De Benedictis, F.M., Colaneri, M., Osimani, P. and Bettuzzi, M.G. (2010) Amino-Terminal Pro-B-Type Natriuretic Peptide in Refractory Kawasaki Disease. Pediatric Cardiology, 30, 837-839.  
https://doi.org/10.1007/s00246-009-9416-3</mixed-citation></ref><ref id="hanspub.30510-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Japanese Circulation Society Joint Working Group (2010) Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease (JCS 2008). Circulation Journal, 74, 1989-2020. 
https://doi.org/10.1253/circj.CJ-10-74-0903</mixed-citation></ref><ref id="hanspub.30510-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kawasaki, T. (1967) Acute Febrile Mucocutaneous Syndrome with Lymphoid Involvement with Specific Desquamation of the Fingers and Toes in Children. Arerugī, 16, 178-222.</mixed-citation></ref><ref id="hanspub.30510-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kawasaki, T., Kosaki, F., Okawa, S., et al. (1974) A New Infantile Acute Febrile Mucocutaneous Lymph Node Syndrome (MLNS) Prevailing in Japan. Pediatrics, 54, 271-276.</mixed-citation></ref><ref id="hanspub.30510-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Burns, J.C., Wiggins Jr., J.W., Toews, W.H., et al. (1986) Clinical Spectrum of Kawasaki Disease in Infants Younger than 6 Months of Age. The Journal of Pediatrics, 109, 759-763. https://doi.org/10.1016/S0022-3476(86)80689-8</mixed-citation></ref><ref id="hanspub.30510-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">O’Loughlin, J.E. (1989) Management of Kawasaki Syndrome: A Con-sensus Statement Prepared by North American Participants of the Third International Kawasaki Disease Symposium, Tokyo, Japan, December, 1988. The Pediatric Infectious, 8, 663-667. https://doi.org/10.1097/00006454-198910000-00001</mixed-citation></ref><ref id="hanspub.30510-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ayusawa, M., Sonobe, T., Uemura, S., et al. (2005) Revision of Diagnostic Guidelines for Kawasaki Disease (the 5th Revised Edition). The Pediatric Infectious, 47, 232-234. https://doi.org/10.1111/j.1442-200x.2005.02033.x</mixed-citation></ref><ref id="hanspub.30510-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Burns, J.C., Kushner, H.I., Bastian, J.F., Shike, H., Shimizu, C., Matsubara, T. and Turner, C.L. (2000) Kawasaki Disease: A Brief History. Pediatrics, 106, 27-37. 
https://doi.org/10.1542/peds.106.2.e27</mixed-citation></ref><ref id="hanspub.30510-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Newburger, J.W., Takahashi, M., Gerber, M.A., et al. (2004) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 110, 2747-2771.https://doi.org/10.1161/01.CIR.0000145143.19711.78</mixed-citation></ref><ref id="hanspub.30510-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, 927-999. https://doi.org/10.1161/CIR.0000000000000484</mixed-citation></ref><ref id="hanspub.30510-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">赵晓东, 杜忠东. 川崎病专题讨论会纪要[J]. 中华儿科杂志, 2007, 45(11): 826-830.</mixed-citation></ref><ref id="hanspub.30510-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Moore, A., Harnden, A. and Mayon-White, R. (2014) Recognising Kawasaki Disease in UK Primary Care: A Descriptive Study Using the Clinical Practice Research Datalink. British Journal of General Practice, 64, e477-e483. 
https://doi.org/10.3399/bjgp14X680953</mixed-citation></ref><ref id="hanspub.30510-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Boudiaf, H. and Achir, M. (2016) The Clinical Profile of Kawasaki Disease in Algerian Children: A Single Institution Experience. Journal of Tropical Pediatrics, 62, 139-143. https://doi.org/10.1093/tropej/fmv090</mixed-citation></ref><ref id="hanspub.30510-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Rowley, A.H. (2015) The Complexities of the Diagnosis and Management of Ka-wasaki Disease. Infectious Disease Clinics of North America, 29, 525-537. https://doi.org/10.1016/j.idc.2015.05.006</mixed-citation></ref><ref id="hanspub.30510-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Seo, Y.-M., Kang, H.-M., Lee, S.-C., Yu, J.-W., Kil, H.-R., Rhim, J.-W., Han, J.-W. and Lee, K.-Y. (2018) Clinical Implications in La-boratory Parameter Values in Acute Kawasaki Disease for Early Diagnosis and Proper Treatment. Korean Journal of Pediatrics, 61, 160-166. https://doi.org/10.3345/kjp.2018.61.5.160</mixed-citation></ref><ref id="hanspub.30510-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Dahdah, N., Siles, A., Fournier, A., Cousineau, J., Delvin, E., Saint-Cyr, C., Spiegelblatt, L., Bonny, Y., Vartian, M. and Montigny, M. (2009) Natriuretic Peptide as an Adjunctive Diagnostic Test in the Acute Phase of Kawasaki Disease. Pediatric Cardiology, 30, 810-817. https://doi.org/10.1007/s00246-009-9441-2</mixed-citation></ref><ref id="hanspub.30510-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">李雪琴, 吕菊红, 李文君. 血浆N端脑利钠肽前体测定在不完全川崎病患儿早期诊断的临床意义[J]. 山西医科大学学报, 2014, 45(3): 227-229.</mixed-citation></ref><ref id="hanspub.30510-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">王祥, 陈智, 肖云彬, 等. 血N末端脑利钠肽原和降钙素原在川崎病诊断中的价值[J]. 中国中西医结合儿科学, 2017, 9(4): 301-303.</mixed-citation></ref><ref id="hanspub.30510-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">李雪琴, 吕菊红, 李文君. 血浆N末端B型利钠肽原与C反应蛋白在小儿川崎病中的变化及临床意义[J]. 中国临床研究, 2014, 27(5): 583-584.</mixed-citation></ref><ref id="hanspub.30510-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Newburger, J.W., Taubert, K.A., Shulman, S.T., Rowley, A.H., Gewitz, M.H., Takahashi, M. and McCrindle, B.W. (2003) Summary and Abstracts of the Seventh International Kawasaki Disease Symposium: December 4-7, 2001, Hakone, Japan. Pediatric Research, 53, 153-157. https://doi.org/10.1203/00006450-200301000-00026</mixed-citation></ref><ref id="hanspub.30510-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">笪小虎, 徐天祥. 川崎病患儿急性期血浆N端脑钠肽前体水平测定的临床意义[J]. 首都医药, 2011(8): 31-32.</mixed-citation></ref><ref id="hanspub.30510-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">顾明, 李斌. 动态测定血浆N-端脑利钠肽在川崎病诊治中的应用[J]. 中国实用医药, 2015, 10(27): 114-115.</mixed-citation></ref><ref id="hanspub.30510-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">范江花, 段蔚, 罗海燕, 等. 血浆N端脑利钠肽前体和降钙素原对早期川崎病冠状动脉损害的预测价值[J]. 儿科药学杂志, 2018, 24(9): 1-5.</mixed-citation></ref><ref id="hanspub.30510-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Cantinotti, M., Clerico, A., Murzi, M., Vittorini, S. and Emdin, M. (2008) Clinical Relevance of Measurement of Brain Natriuretic Peptide and N-Terminal Pro-Brain Natriuretic Peptide in Pediatric Cardiology. Clinica Chimica Acta, 390, 12-22. https://doi.org/10.1016/j.cca.2007.12.020</mixed-citation></ref><ref id="hanspub.30510-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">李璟昊, 王虹, 邢艳琳, 等. 小儿心内膜弹力纤维增生症血浆脑钠肽/N端脑钠肽前体与左室射血分数的相关性研究[J]. 东南大学学报(医学版), 2016, 35(1): 26-31.</mixed-citation></ref><ref id="hanspub.30510-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">王轶娜, 杨宇, 陈平, 等. 无创正压通气对慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭患者血浆N端脑利钠肽前体水平的影响[J]. 中南大学学报(医学版), 2012, 37(4): 325-331.</mixed-citation></ref><ref id="hanspub.30510-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">高艺花, I-Seok Kang, Geena Kim. 肺动脉高压患儿血浆N端脑利钠肽前体和右心室Tei指数相关性研究[J]. 中国实用儿科杂志, 2013, 28(7): 525-528.</mixed-citation></ref></ref-list></back></article>